The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated RAS-mutant metastatic pancreatic cancer, according to a Phase I/II ...

Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, and HRAS. RAS-family mutations are associated with numerous types of cancer.

The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard ...

The data published in NEJM reflect outcomes in the PDAC cohort from the RMC-6236-001 trial (NCT05379985), an open-label, multicenter Phase 1/2 trial evaluating daraxonrasib monotherapy in patients ...

Hugo Lavoie is at the Institute for Research in Immunology and Cancer, Université de Montréal, Montreal, Quebec H3C 3J7, Canada. Marc Therrien is at the Institute for Research in Immunology and Cancer ...

The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS, and a key ...

Proteins that are commonly mutated and overexpressed in cancers are called oncoproteins and are typical targets for cancer therapies. Cancer treatment faces significant challenges due to the presence ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, side effects and when it could reach patients.

After debunking earlier rumors that it was acquiring RAS superstar Revolution Medicines, AbbVie is now taking a more ...

Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” ...

Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities Histology-agnostic therapies: by focusing on common mutations across various cancers, this approach ...